The funding round included participation from DeepWork Capital, alongside follow-on investments from Antler, Beyond Utility Water Ventures, and the Deming Center Venture Fund. Biota intends to use the proceeds to scale its commercial operations and further develop its diagnostic platform, which currently features the RapidTest screening tool for 15-minute results and the MagnaPrep system for streamlined sample preparation.

Founder and CEO Rose Nash noted that while PFAS treatment methods are evolving, measurement capabilities have lagged behind, creating bottlenecks for organizations attempting to map contamination. By moving into a new 7,500-square-foot facility in Colorado, the company is positioning itself to expand its reach beyond "forever chemicals" to include other environmental hazards such as microplastics. The startup has already secured support from the National Institutes of Health and the State of Colorado’s Advanced Industries Program to fuel these efforts.